Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
|ClinicalTrials.gov Identifier: NCT01615120|
Recruitment Status : Unknown
Verified February 2016 by GTx.
Recruitment status was: Active, not recruiting
First Posted : June 8, 2012
Last Update Posted : February 9, 2016
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||March 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, Dalton JT, Steiner MS. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41. doi: 10.1016/j.eururo.2014.06.011. Epub 2014 Jun 24.